Canurta Journal

The waitlist is now open for Dual Relief Drops™, Dual Relief Drops™ Extra Strength, and Amarazan™, three new wellness products launching this month from our team.

Canurta Naturals has launched its updated website for natural ingredient customers and introduced Hemp Flavonoid Complex™, a proprietary concentration of cannflavin-rich flavonoids designed to support oxidative balance and two pathways associated with inflammation.

Canurta Therapeutics, in collaboration with International Business University (IBU), is co-hosting SOVEREIGN 2026, a one-day flagship event taking place on May 28, 2026, in downtown Toronto as part of Toronto Tech Week.

Canurta announced a partnership with extractX Ltd. in connection with extractX’s enhanced Extraction Mobile Lab platform (EML 2.0). Under this collaboration, extractX is leveraging Canurta’s patented extraction processes within its pharma-grade mobile laboratory infrastructure.

Canurta has completed the first tranche of its previously announced transaction with PharmaDrug Inc. (CSE: PHRX), solidifying a strategic path toward public market access. Under this agreement, PharmaDrug has acquired an initial equity interest of 19.9% in Canurta, with the potential to increase to 40% pending future milestones and regulatory approvals.

As 2025 comes to a close, Canurta is proud to share the milestones that shaped a year of significant scientific and strategic advancement.

Merger with PharmaDrug Progresses Towards Closing Following the execution of a definitive agreement in Q4, Canurta continues to work toward the initial closing of its strategic merger with PharmaDrug Inc. (CSE: PHRX.CN). This agreement is a key component of Canurta’s growth strategy and public market alignment, supporting operational scale and long-term capital planning. Extraction Acquisition Target Under Review In parallel, Canurta is progressing toward a definitive agreeme

Definitive Agreement Signed with PHRX: Canurta Advances Public Market Strategy Canurta Therapeutics has signed a Definitive Agreement with PharmaDrug Inc. (CSE: PHRX.CN), formalizing the terms of the proposed acquisition of up to 40 percent of Canurta. This agreement marks a key step forward in Canurta’s strategy to access the public markets, building on the previously announced LOI and reinforcing its focus on long-term growth and capital efficiency. The partnership is desig

In August 2025, Canurta launched the Satoshi Trials to integrate Bitcoin into its treasury model, achieved a key blood-brain barrier milestone for CNR-401, signed a public market LOI with PharmaDrug, and CEO Akeem Gardner spoke on innovation at CanadianSME and the Black Blockchain Summit.

In July 2025, Canurta signed an LOI with PharmaDrug Inc., joined Next Sequence’s AI x Bio Accelerator, discovered new bioactive flavonoids, and shared promising data on glioblastoma and ALS models—all while preparing for C2MP Final Pitch Day.

In June 2025, Canurta signed a Letter of Intent to merge with extractX Ltd., advanced CNR-401 through preclinical development, unveiled new data at ENCALS, and launched the alpha version of its AI-powered Polykye™ platform.

In May 2025, Canurta advanced preclinical studies for CNR-401, showcased CNR-301 at MedCity INVEST, launched an open-source platform via the Base Batch Buildathon, and graduated from the CDL Neuro 2024/25 cohort.

In April 2025, Canurta Therapeutics was named a finalist for MedCity INVEST, made breakthroughs in biosynthesis and AI drug discovery, and celebrated CEO Akeem Gardner's recognition as one of Canada's Top 20 Under 40 in Life Sciences.

In February 2025, Canurta Therapeutics achieved key regulatory milestones with Pre-IND and Orphan Drug submissions for CNR-401. We also expanded preclinical studies with WSU, enhanced AI-driven quality control, and gained traction in the C2MP U.S. expansion program.

In February 2025, Canurta Therapeutics achieved key regulatory milestones with Pre-IND and Orphan Drug submissions for CNR-401. We also expanded preclinical studies with WSU, enhanced AI-driven quality control, and gained traction in the C2MP U.S. expansion program.

In January 2025, Canurta joined the prestigious Canada-Chicago Mentoring Program, connected with industry leaders at the J.P. Morgan Healthcare Conference, shared research at the SUNY Cannabis Conference, and advanced its Pre-IND milestones with the FDA.

This month, Canurta presented groundbreaking ALS research at the ALS/MND Symposium, shared insights with Lambton College, appeared on The Global Marketing Show, and continued scientific advances in biosynthesis and molecular fingerprinting.

Canurta Therapeutics presents new research at the ALS/MND Symposium, explores next-gen therapeutics at CB1 & CB2 Summit, joins NVIDIA Inception and Canada-Chicago Mentoring Program, and continues breakthroughs in bioinformatics and ALS biomarker discovery.

CEO Akeem Gardner reflects on Canurta’s momentum this fall, from securing $2.25M in commitments to pitching at ACT Canada, publishing new findings on Cannabistilbene I, joining the CDL program for arthritis, and advancing biomarker research for ALS.

CEO Akeem Gardner shares positive biotech market outlook and Canurta’s latest milestones, including early Pre-Seed traction, showcasing at CHFA, investor engagement at RESI Boston, and continued advances in flavonoid drug development and ALS biomarker research.